S13:E1 – Oncology Morning Commute: Patient Selection for Treatment With PARP Inhibitors in Ovarian Cancer

Hematology / Oncology @Point of Care Podcasts

English - December 16, 2022 04:08 - 29 minutes - 40.7 MB
Medicine Health & Fitness checkpointinhibitors cmece endometrialcancer immunotherapy Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: S12:E3 – Oncology Morning Commute: Shifting Treatment Sequences in the Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape

Next Episode: S13:E2 – Oncology Morning Commute: Managing Adverse Events That Occur With PARP Inhibition Therapies—What Your Patients Need to Know

What is the history behind the development of PARP inhibitors for the treatment of ovarian cancer and how have they influenced recent guideline changes regarding their use? Our faculty discuss this and more in the first podcast of the three-part series on PARP inhibitors and ovarian cancer.

Visit http://www.MorningCommutePodcast.com/OvarianCancer1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit